HopeStage
Back to all studies
RecruitingNCT06843044

Ranquilon or Afobazole for anxiety and adjustment difficulties

About this titleRead the official source — NCT06843044

Researchers are comparing Ranquilon and Afobazole to find out how the approaches affect anxiety symptoms in people with an anxiety condition.

Medication studyAges 18–70RussiaAdjustment disorder
The study in practice

Understand this study

What is this study about?

Researchers are comparing Ranquilon and Afobazole to find out how the approaches affect anxiety symptoms in people with an anxiety condition.

Who could participate?

This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

Listed locations
Engel's and 5 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 13, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
250
Sponsor
Valenta Pharm JSC
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Russia
Age range
From 18 Years to 70 Years
Official registry ID
NCT06843044
Official title
Show the full official title

An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

Recruitment & locations

Currently recruiting

Engel's, Russia · Moscow, Russia · Saint Petersburg, Russia

2 more locations
  • Saratov, Russia
  • Russia
Registry details
Registry conditions (original wording)

Anxiety; Neurasthenia; Adjustment Disorders

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Ranquilon and Afobazole to find out how the approaches affect anxiety symptoms in people with an anxiety condition.

Who is behind this study?

The study sponsor is Valenta Pharm JSC.

Does this study involve medication?

Yes. The study involves medication, including Ranquilon and Afobazole.

Who can participate?

This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies